Search
Vistagen Therapeutics Inc
VTGNAdd to Watchlist
0.241USD
0.0000.00%
Close 07-31 16:00（ET）Quotes delayed by 15 min
9.55MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Vistagen Therapeutics Inc is 6.00, ranking 331 out of 385 in the Biotechnology & Medical Research industry. The average price target is 13.50, with a high of 19.00 and a low of 12.00.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
3.725
Target Price
+1431.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Vistagen Therapeutics Inc
VTGN
5
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Vistagen Therapeutics Inc's expected revenue for the next quarter?
Vistagen Therapeutics Inc's expected revenue is 250.00K.
What is Vistagen Therapeutics Inc's price target?
Analysts forecast that Vistagen Therapeutics Inc's price target is USD 13.50, with the highest forecast at USD 19.00 and the lowest forecast at USD 12.00.
How have Vistagen Therapeutics IncVTGN's recent earnings per share performed?
The market expectation was USD -0.38, while Vistagen Therapeutics IncVTGN's earnings per share (EPS) for the previous quarter was USD -0.45. EPS for the next quarter is expected at USD -0.36.
What is the analyst rating for Vistagen Therapeutics Inc?
Based on the ratings of Vistagen Therapeutics Inc's stock from 5 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.